<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011369</article-id><article-id pub-id-type="publisher-id">ACM-38482</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_75134454.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  245例消化系统神经内分泌肿瘤的内镜表现及病理特征分析
  Endoscopic Manifestations and Pathological Features of 245 Cases of Neuroendocrine Tumors in the Digestive System
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>党</surname><given-names>智萍</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>婷</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>翟</surname><given-names>慧敏</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>诗梦</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孔</surname><given-names>心涓</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院消化内科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2444</fpage><lpage>2450</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨消化系统神经内分泌肿瘤(Neuroendocrine tumors, NETs)的流行病学、内镜表现及临床病理特征，以提高对该类疾病的诊治水平。方法：回顾性分析青岛大学附属医院消化内科自2013年2月至2020年9月诊断为NETs患者的临床资料，探讨其流行病学、内镜表现及临床病理特征。结果：共检出消化系统NETs患者245例，男性130例(53.1%)，女性115例(46.9%)，平均年龄(53.3 &#177; 12.3)岁。消化系统NETs好发部位以结直肠(127例，51.8%)和胃(81例，33.1%)最常见。肿瘤直径 ≤ 10.0 mm的患者有209例(85.3%)；10.0~20.0 mm25例(10.2%)；&gt;20.0 mm 11例(4.5%)。病变多起源于黏膜肌层(55.4%)及黏膜下层(43.8%)。根据WHO分类标准，245例患者病理分期为NETG1的有204例(83.3%)；NETG2的有40例(16.3%)；NEC的有1例(0.4%)。免疫组化染色结果显示，Syn阳性率为95.1%，CgA阳性率为55.1%。上消化道与下消化道NETs在性别(P = 0.001)、肿瘤大小(P &lt; 0.001)及病理分型(P &lt; 0.001)存在统计学差异。结论：消化系统NETs的好发部位以结直肠和胃最常见。肿瘤直径绝大多数不超过10.0 mm，病变多起源于黏膜肌层及黏膜下层。ESD是既安全又有效的微创治疗方法。超声内镜对消化系统NETs具有较大的诊断价值。
    Objective: To investigate the epidemiology, endoscopic manifestations and clinicopathological features of neuroendocrine tumors of the digestive system in order to improve the diagnosis and treatment of these diseases. Method: The clinical data of NETs patients diagnosed in department of Gastroenterology, Affiliated Hospital of Qingdao University from February 2013 to September 2020 were retrospectively analyzed to investigate the epidemiology, endoscopic manifestations and clinicopathological features. Results: A total of 245 patients with digestive NETs were detected, including 130 males (53.1%) and 115 females (46.9%), with an average age of 53.3 &#177; 12.3 years. The most common sites of gastrointestinal NETs were the colorectal (127 cases, 51.8%) and the stomach (81 cases, 33.1%). There were 209 patients (85.3%) with tumor diameter ≤ 10.0 mm. 25 patients (10.2%) with tumor diameter between 10.0 - 20.0 mm; 11 patients (4.5%) with tumor diameter &gt; 20.0 mm. The tumor mostly originated in the muscularis mucosa (55.4%) and submucosa (43.8%). According to WHO classification criteria, 204 (83.3%) of 245 patients were diagnosed as NETG1 in pathological stage; 40 (16.3%) patients were diagnosed as NETG2; and only 1 (0.4%) patient were in NEC. The immunohistochemical staining results showed that the positive rate of Syn and CgA were 95.1% and 55.1% respectively. There were statistically significant differences between upper and lower gastrointestinal NETs in gender (P = 0.001), tumor size (P &lt; 0.001), and pathological type (P &lt; 0.001). Conclusion: Colorectal and stomach are the most common sites of gastrointestinal NETs. Most of the tumors are no more than 10.0 mm in diameter, and most of the lesions originate from the mucosal musculus and submucosa. ESD is a safe and effective minimally invasive treatment. Endoscopic ultrasonography is of great diagnostic value for NETs in the digestive system. 
  
 
</p></abstract><kwd-group><kwd>神经内分泌肿瘤，消化系统，流行病学，内镜表现，病理特征, Neuroendocrine Tumor</kwd><kwd> Digestive System</kwd><kwd> Epidemiology</kwd><kwd> Endoscopic Manifestations</kwd><kwd> Pathological Features</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨消化系统神经内分泌肿瘤(Neuroendocrine tumors, NETs)的流行病学、内镜表现及临床病理特征，以提高对该类疾病的诊治水平。方法：回顾性分析青岛大学附属医院消化内科自2013年2月至2020年9月诊断为NETs患者的临床资料，探讨其流行病学、内镜表现及临床病理特征。结果：共检出消化系统NETs患者245例，男性130例(53.1%)，女性115例(46.9%)，平均年龄(53.3 &#177; 12.3)岁。消化系统NETs好发部位以结直肠(127例，51.8%)和胃(81例，33.1%)最常见。肿瘤直径 ≤ 10.0 mm的患者有209例(85.3%)；10.0~20.0 mm25例(10.2%)；&gt;20.0 mm 11例(4.5%)。病变多起源于黏膜肌层(55.4%)及黏膜下层(43.8%)。根据WHO分类标准，245例患者病理分期为NETG1的有204例(83.3%)；NETG2的有40例(16.3%)；NEC的有1例(0.4%)。免疫组化染色结果显示，Syn阳性率为95.1%，CgA阳性率为55.1%。上消化道与下消化道NETs在性别(P = 0.001)、肿瘤大小(P &lt; 0.001)及病理分型(P &lt; 0.001)存在统计学差异。结论：消化系统NETs的好发部位以结直肠和胃最常见。肿瘤直径绝大多数不超过10.0 mm，病变多起源于黏膜肌层及黏膜下层。ESD是既安全又有效的微创治疗方法。超声内镜对消化系统NETs具有较大的诊断价值。</p></sec><sec id="s2"><title>关键词</title><p>神经内分泌肿瘤，消化系统，流行病学，内镜表现，病理特征</p></sec><sec id="s3"><title>Endoscopic Manifestations and Pathological Features of 245 Cases of Neuroendocrine Tumors in the Digestive System<sup> </sup></title><p>Zhiping Dang<sup>1</sup>, Ting Yu<sup>1</sup>, Huimin Zhai<sup>1</sup>, Shimeng Wang<sup>1</sup>, Xinjuan Kong<sup>2*</sup></p><p><sup>1</sup>Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Gastroenterology, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/3-1571651x5_hanspub.png" /></p><p>Received: Oct. 11<sup>th</sup>, 2020; accepted: Oct. 28<sup>th</sup>, 2020; published: Nov. 4<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/3-1571651x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the epidemiology, endoscopic manifestations and clinicopathological features of neuroendocrine tumors of the digestive system in order to improve the diagnosis and treatment of these diseases. Method: The clinical data of NETs patients diagnosed in department of Gastroenterology, Affiliated Hospital of Qingdao University from February 2013 to September 2020 were retrospectively analyzed to investigate the epidemiology, endoscopic manifestations and clinicopathological features. Results: A total of 245 patients with digestive NETs were detected, including 130 males (53.1%) and 115 females (46.9%), with an average age of 53.3 &#177; 12.3 years. The most common sites of gastrointestinal NETs were the colorectal (127 cases, 51.8%) and the stomach (81 cases, 33.1%). There were 209 patients (85.3%) with tumor diameter ≤ 10.0 mm. 25 patients (10.2%) with tumor diameter between 10.0 - 20.0 mm; 11 patients (4.5%) with tumor diameter &gt; 20.0 mm. The tumor mostly originated in the muscularis mucosa (55.4%) and submucosa (43.8%). According to WHO classification criteria, 204 (83.3%) of 245 patients were diagnosed as NETG1 in pathological stage; 40 (16.3%) patients were diagnosed as NETG2; and only 1 (0.4%) patient were in NEC. The immunohistochemical staining results showed that the positive rate of Syn and CgA were 95.1% and 55.1% respectively. There were statistically significant differences between upper and lower gastrointestinal NETs in gender (P = 0.001), tumor size (P &lt; 0.001), and pathological type (P &lt; 0.001). Conclusion: Colorectal and stomach are the most common sites of gastrointestinal NETs. Most of the tumors are no more than 10.0 mm in diameter, and most of the lesions originate from the mucosal musculus and submucosa. ESD is a safe and effective minimally invasive treatment. Endoscopic ultrasonography is of great diagnostic value for NETs in the digestive system.</p><p>Keywords:Neuroendocrine Tumor, Digestive System, Epidemiology, Endoscopic Manifestations, Pathological Features</p><disp-formula id="hanspub.38482-formula8"><graphic xlink:href="//html.hanspub.org/file/3-1571651x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1571651x8_hanspub.png" /> <img src="//html.hanspub.org/file/3-1571651x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>神经内分泌肿瘤(Neuroendocrine Tumors, NETs)是一组起源于肽能神经元和神经内分泌细胞的异质性肿瘤 [<xref ref-type="bibr" rid="hanspub.38482-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.38482-ref2">2</xref>]，占所有恶性肿瘤的1%~2% [<xref ref-type="bibr" rid="hanspub.38482-ref3">3</xref>]，可发生于身体任何部位，其中以消化系统胃肠胰神经内分泌肿瘤最为常见，约占全部神经内分泌肿瘤的70%~75% [<xref ref-type="bibr" rid="hanspub.38482-ref4">4</xref>]。NETs一直被认为是一种发病率极低的罕见疾病，但近20年的研究数据显示，NETs的发病率呈明显上升趋势 [<xref ref-type="bibr" rid="hanspub.38482-ref5">5</xref>]。根据肿瘤的形态学、增殖活性及分化程度，NETs可分为神经内分泌瘤(Neuroendocrine Tumor, NET)、神经内分泌癌(Neuroendocrine Carcinoma, NEC)以及混合型腺神经内分泌癌(Mixed Adenoneuroendocrine Carcinoma, MANEC) [<xref ref-type="bibr" rid="hanspub.38482-ref6">6</xref>]。由于缺乏相关流行病学调查数据，特异的临床表现及相关诊治经验，使得NETs的诊疗进展受到一定限制。本研究通过回顾性分析青岛大学附属医院消化内科自2013年2月至2020年9月诊断为NETs的245例患者的临床资料，探讨其流行病学、内镜表现及临床病理特征，以期为该病的预防和规范化诊治提供相关参考依据。</p></sec><sec id="s6"><title>2. 资料和方法</title><sec id="s6_1"><title>2.1. 临床资料</title><p>本研究回顾性分析了青岛大学附属医院消化内科自2013年2月至2020年9月收治的245例患者的临床资料。纳入标准：结合超声内镜及病理结果诊断为消化系统神经内分泌肿瘤。在245例患者中，男性130例(53.1%)，女性115例(46.9%)，男女比例为1.13:1。平均年龄(53.3 &#177; 12.3)岁，中位年龄54 (13~79)岁。2013、2014、2015、2016、2017、2018、2019以及2020年上半年NETs患者所占的比例分别为：0.8%、1.2%、11.8%、20.0%、17.1%、17.6%、18.8%、12.7%。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><sec id="s6_2_1"><title>2.2.1. 资料收集</title><p>回顾性收集全部消化系统NETs患者的发病时间、性别、年龄、肿瘤部位、肿瘤大小、肿瘤起源、内镜特点、病理特征、WHO分类、诊疗及预后等数据。全部数据资料由研究者本人及病理科医师按照统一标准进行检索、收集及记录。资料采集已征得患者本人同意，并将个人信息严格保密，符合医学伦理要求。</p></sec><sec id="s6_2_2"><title>2.2.2. 免疫组织化学染色</title><p>每例患者的病理组织经过福尔马林固定、石蜡包埋、化学染色。免疫组化染色包括Syn、CgA、Ki-67染色。另外，若需要鉴别诊断，可根据肿瘤部位补充免疫组化类型。</p></sec><sec id="s6_2_3"><title>2.2.3. 诊断标准及病理分级</title><p>NETs的诊断标准参照2010年世界卫生组织(WHO)以及北美神经内分泌肿瘤学会(NANETS)分类标准 [<xref ref-type="bibr" rid="hanspub.38482-ref7">7</xref>]。病理分级依据WHO 2019NETs分类标准 [<xref ref-type="bibr" rid="hanspub.38482-ref8">8</xref>]，分为神经内分泌瘤、神经内分泌癌和混合型腺神经内分泌癌，其中神经内分泌瘤分为神经内分泌瘤I级(G1)、神经内分泌瘤2级(G2)和神经内分泌瘤3级(G3)；神经内分泌癌分为小细胞型(SCNEC)和大细胞型(LCNEC)。当核分裂象与Ki-67指数不一致时，以级别高的为准。</p></sec></sec><sec id="s6_3"><title>2.3. 统计学方法</title><p>采用SPSS 26.0统计软件进行统计学分析。符合正态分布的计量资料以 X &#175; &#177; S表示，组间比较采用t检验或方差分析；计数资料组间比较采用X2检验或Fisher确切概率法。P &lt; 0.05具有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 消化系统NETs患者流行病学特征</title><p>本研究共纳入245例消化系统NETs患者，男性130例(53.1%)，女性115例(46.9%)，男女比例为1.13:1。患者的平均年龄(53.3 &#177; 12.3)岁，40岁及以下的患者35例(14.3%)，大于40岁的患者210例(85.7%) (见表1)。2013、2014、2015、2016、2017、2018、2019以及2020年前9月诊断NETs患者所占的比率分别是：0.8%、1.2%、11.8%、20.0%、17.1%、17.6%、18.8%、12.7% (见表2)，随时间变化整体呈逐年上升趋势，2020年前9个月检出患者31例(12.7%)。NETs患者的男女性别比例呈逐年缩小趋势，2015年NETs患者男女性别比为1.63:1，2019年下降至0.84:1。各年份NETs患者的平均年龄分别为：32.5岁、49.0岁、51.0岁、53.3岁、54. 8岁、55.3岁、52.3岁、54.1岁，2013年至2018年NETs患者的平均年龄逐年增加，2019、2020略有下降。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution and clinicopathological characteristics of gastrointestinal NETs in 245 cases, n</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >项目</th><th align="center" valign="middle"  rowspan="2"  >食管</th><th align="center" valign="middle"  rowspan="2"  >胃</th><th align="center" valign="middle"  rowspan="2"  >十二指肠</th><th align="center" valign="middle"  rowspan="2"  >结直肠</th><th align="center" valign="middle"  rowspan="2"  >胰腺</th><th align="center" valign="middle"  rowspan="2"  >阑尾</th><th align="center" valign="middle"  rowspan="2"  >总计</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >(上消化道vs下消化道)</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >80</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >130 (53.1%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >115 (46.9%）</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.06</td></tr><tr><td align="center" valign="middle" >≤40</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >35 (14.3%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&gt;40</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >73</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >104</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >210 (85.7%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >直径(mm)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >≤10.0</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" >17</td><td align="center" valign="middle" >123</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >209 (85.3%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >10.0~20.0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >25 (10.2%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&gt;20.0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >11 (4.5%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >起源</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.091</td></tr><tr><td align="center" valign="middle" >粘膜肌层</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >76</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >133 (55.4%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >粘膜下层</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >37</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >51</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >105 (43.8%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >固有肌层</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >2 (0.8%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >WHO分类</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >NETG1</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >119</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >204 (83.3%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >NETG2</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >27</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >40 (16.3%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >NEC</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >1 (0.4%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >MANEC</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0 (0.0%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >免疫组化</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Syn阳性</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >124</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >233 (95.1%)</td><td align="center" valign="middle" >0.194</td></tr><tr><td align="center" valign="middle" >CgA阳性</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >135 (55.1%)</td><td align="center" valign="middle" >0.793</td></tr><tr><td align="center" valign="middle" >总计</td><td align="center" valign="middle" >4 (1.6%)</td><td align="center" valign="middle" >81 (33.1%)</td><td align="center" valign="middle" >24 (9.8%)</td><td align="center" valign="middle" >127 (51.8%)</td><td align="center" valign="middle" >5 (2.1%)</td><td align="center" valign="middle" >4 (1.6%)</td><td align="center" valign="middle" >245 (100.0%)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 245例消化系统NETs的部位分布及其临床病理特征n(%)</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The proportion of NETs patients from 2013 to 202</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >总病例数</th><th align="center" valign="middle" >概率(%)</th><th align="center" valign="middle" >男</th><th align="center" valign="middle" >女</th><th align="center" valign="middle" >性别比</th><th align="center" valign="middle" >年龄</th></tr></thead><tr><td align="center" valign="middle" >2013</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >0.8%</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.00:1</td><td align="center" valign="middle" >32.5</td></tr><tr><td align="center" valign="middle" >2014</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >1.2%</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2.00:1</td><td align="center" valign="middle" >49.0</td></tr><tr><td align="center" valign="middle" >2015</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >11.8%</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >1.63:1</td><td align="center" valign="middle" >51.0</td></tr><tr><td align="center" valign="middle" >2016</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >20.0%</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >1.04:1</td><td align="center" valign="middle" >53.3</td></tr><tr><td align="center" valign="middle" >2017</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" >17.1%</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >1.21:1</td><td align="center" valign="middle" >54.8</td></tr><tr><td align="center" valign="middle" >2018</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >17.6%</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >1.05:1</td><td align="center" valign="middle" >55.3</td></tr><tr><td align="center" valign="middle" >2019</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >18.8%</td><td align="center" valign="middle" >21</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >0.84:1</td><td align="center" valign="middle" >52.3</td></tr><tr><td align="center" valign="middle" >2020</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >12.7%</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >1.38:1</td><td align="center" valign="middle" >54.1</td></tr><tr><td align="center" valign="middle" >总计</td><td align="center" valign="middle" >245</td><td align="center" valign="middle" >100%</td><td align="center" valign="middle" >130</td><td align="center" valign="middle" >115</td><td align="center" valign="middle" >1.13:1</td><td align="center" valign="middle" >53.3</td></tr></tbody></table></table-wrap><p>表2. 2013~2020年NETs患者所在比率分析</p></sec><sec id="s7_2"><title>3.2. 消化系统NETs的患病部位及镜下肿瘤特征</title><p>本研究显示，245例消化系统NETs的好发部位以结直肠(127例，51.8%)、胃(81例，33.1%)和十二指肠(24例，9.8%)最常见，其余部位还包括食管(4例，1.6%)、胰腺(5例，2.1%)、阑尾(4例，1.6%)。病变位于上消化道109例(44.5%)，下消化道131例(53.5%)。消化系统NETs在普通内镜下表现为黏膜下隆起,超声内镜主要表现为低回声或中-低回声、边界清晰、回声均匀的圆形病灶。肿瘤直径 ≤ 10.0 mm的209例，占85.3%；10.0~20.0 mm的25例，占10.2%；&gt;20.0 mm的11例，占4.5%。病变多起源于黏膜肌层(55.4%)及黏膜下层(43.8%)，0.8%起源于固有肌层。</p></sec><sec id="s7_3"><title>3.3. 消化系统NETs的治疗方式及病理特征</title><p>诊断为消化系统NETs的245例患者中，行内镜下粘膜剥离术(ESD)治疗的有170例(69.4%)，行内镜下粘膜切除术(EMR)治疗的有40例(16.3%)，行外科手术治疗的有6例(2.4%)。根据WHO分类标准，245例患者病理分期为NETG1的有204例，占83.3%；NETG2的有40例，占16.3%；NEC的有1例，仅占0.4%。免疫组化染色结果显示，Syn阳性率为95.1%，CgA阳性率为55.1%。</p></sec><sec id="s7_4"><title>3.4. 不同部位消化道NETs影响因素及特征分析</title><p>本研究将消化系统NETs病变部位不同分为上消化道NETs (109例)及下消化道NETs (131例)。统计学分析显示，上消化道与下消化道NETs在性别(P = 0.001)、肿瘤大小(P &lt; 0.001)及病理分型(P &lt; 0.001)存在统计学差异；但在年龄(P = 0.06)、肿瘤起源(P = 0.091)、免疫组化方面(Syn，P = 0.194；CgA，P = 0.793)尚无统计学意义。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>神经内分泌肿瘤(NETs)是起源于肽能神经元和神经内分泌细胞的异质性肿瘤，可位于身体任何组织器官。而胃肠道是常见的发病部位之一，约占NETs的50.6% [<xref ref-type="bibr" rid="hanspub.38482-ref9">9</xref>]。近年来，由于国家经济发展，国民健康意识提高，消化内镜检查不断普及，消化系统NETs的发病率呈逐年上升趋势 [<xref ref-type="bibr" rid="hanspub.38482-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.38482-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.38482-ref12">12</xref>]。本研究队列中消化系统NETs患者所占的比率随时间变化整体呈逐年上升趋势；另外，NETs患者的男女性别比例呈逐年缩小趋势，由2015年的1.63:1降至2019年的0.84。此结论与国内其他研究结果是一致的 [<xref ref-type="bibr" rid="hanspub.38482-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.38482-ref14">14</xref>]。在本研究队列中，85.7%患者的患病年龄在40岁以上，2013年至2018年NETs患者的平均年龄逐年增加，2019、2020略有下降，这可能与消化内镜检查的不断普及相关。</p><p>有国外学者对35825例NETs患者资料分析发现 [<xref ref-type="bibr" rid="hanspub.38482-ref9">9</xref>]，其好发部位依次为直肠、胰腺和胃；另一项研究发现 [<xref ref-type="bibr" rid="hanspub.38482-ref9">9</xref>]，不同性别患者NETs的原发部位不同，女性的原发部位多在肺、胃、阑尾或盲肠，而男性则更多发生于胸腺、十二指肠、胰腺、空回肠或直肠。在本研究中，消化系统NETs好发于结直肠、胃以及十二指肠部位。不同性别患者消化系统NETs的好发部位有所不同。女性的好发部位主要是胃，而男性患者的好发部位是结直肠，本结论与其他国内外研究结果相类似 [<xref ref-type="bibr" rid="hanspub.38482-ref15">15</xref>]。消化内镜检查对于消化系统NETs的诊断、治疗及术后随访等方面有重要作用，而超声内镜检查可以对黏膜下肿物的起源、大小、与周围组织器官的毗邻关系进行评估，为后续肿瘤治疗方式的选择提供依据。消化系统NETs在普通内镜下表现为椭圆形、半球状或息肉样黏膜下隆起，表面可见迂曲的血管，有时也可表现为溃疡。超声内镜主要表现为低回声或中–低回声、边界清晰的圆形病灶，本研究发现，消化系统NETs病变多起源于黏膜肌层及黏膜下层，大多数肿瘤直径 ≤ 10.0 mm。此结论与一些国内学者苏慧等人的研究结果基本上是一致的 [<xref ref-type="bibr" rid="hanspub.38482-ref16">16</xref>]：其研究的167例胃肠道NETs患者中，56.0%的病变位于粘膜层，41.6%位于粘膜下层；肿瘤直径 ≤ 10.0 mm的患者占88.0%。</p><p>NETs是一种潜在的恶性肿瘤，其生长缓慢、病程较长，预后较好，早期的诊断和治疗能够显著提高患者生存质量及预后。消化系统NETs缺乏典型的临床表现，仅凭内镜尚不能对其进行确诊，需要免疫组化等病理组织学检测进一步鉴别诊断。嗜铬粒蛋白A (CgA)和突触素(Syn)是最常用来确定肿瘤是否具有神经内分泌分化性质的免疫组织化学标记物 [<xref ref-type="bibr" rid="hanspub.38482-ref17">17</xref>]。神经内分泌瘤(NET)可根据核分裂象数和Ki-67指数分为NETG1和NETG2两组。G1：核分裂象 &lt; 2/10HPF (高倍视野)，Ki-67 &lt; 2%；G2：核分裂象2-20/10HPF，Ki-67为3%~20% [<xref ref-type="bibr" rid="hanspub.38482-ref18">18</xref>]。在本研究中，研究患者的免疫组化结果显示,CgA阳性率为55.1%，Syn阳性率为95.1%。结合相关研究报道 [<xref ref-type="bibr" rid="hanspub.38482-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.38482-ref20">20</xref>]，免疫组化在辅助诊断NETs方面是不可替代的，其中CgA、Syn可作为必查项目，Ki-67表达的检测有助于NETs的分类。另外，在本研究中，83.3%的患者病理分期为NETG1，16.3%患者的病理分期为NETG2。这与我国23家医院多中心研究报道的NETG1期患者占75.8%，NETG2期患者占11.8%的研究结果基本一致 [<xref ref-type="bibr" rid="hanspub.38482-ref21">21</xref>]。</p><p>消化系统NETs的治疗方式取决于病变的部位、数量、大小、深度以及有无淋巴结及周围器官转移等。起源于粘膜层或粘膜下层的，直径 ≤ 10.0 mm的NETs可行EMR或ESD治疗；直径 &gt; 20 mm的NETs则通常选择外科手术治疗，必要时行淋巴结清扫 [<xref ref-type="bibr" rid="hanspub.38482-ref22">22</xref>]。如果肿瘤直径在10~20 mm之间，则需要消化内科医师及外科手术医师综合评估后选择最佳治疗方案。</p><p>本研究中有209例(85.3%)患者的肿瘤最大直径在10 mm以内，其中162例在完善超声内镜检查后行ESD治疗。25例(10.2%)患者的肿瘤直径在10~20 mm之间，其中8例行ESD治疗。经ESD治疗后的患者在随访过程中均未发现肿瘤复发。11例(4.5%)患者的肿瘤直径 &gt; 20.0 mm，其中6例患者行外科手术治疗，术后随访中未见复发。相关文献表明，ESD是消化系统NETs治疗的安全、有效方法，其对病变的完整切除率明显高于传统的EMR治疗 [<xref ref-type="bibr" rid="hanspub.38482-ref23">23</xref>]。因此，我们需要对NETs患者的临床表现、超声内镜特征及组织病理特征综合分析，选择合适的治疗方案。</p><p>本研究通过单因素统计分析得出，上消化道与下消化道NETs在患者的性别、内镜下肿瘤直径及组织病理分型方面存在统计学差异。上消化道NETs患者女性居多，而下消化道患者男性居多。上消化道NETs患者有76.1%肿瘤直径小于10.0 mm，83.3%组织病理类型为NETG1，而下消化道NETs患者有高达96.2%肿瘤直径小于10.0 mm，93.7%组织病理类型为NETG2。另外，上消化道与下消化道NETs则在患者年龄、肿瘤起源深度及免疫组化类型方面尚无统计学意义。</p><p>综上所述，消化系统NETs的好发部位以结直肠和胃最常见，低回声或中–低回声、边界清晰、回声均匀的圆形病灶是其在超声内镜下的典型表现。肿瘤直径绝大多数不超过10.0 mm，病变多起源于黏膜肌层及黏膜下层。治疗上可选择内镜ESD、EMR治疗、手术治疗及放化疗，对于病变仅局限于黏膜下层的NETs，ESD是既安全又有效的微创治疗方法。超声内镜对消化系统NETs具有较大的诊断价值，根据内镜下不同的特征表现及病变的分期分级，可选择不同的治疗方式。另外，对于上消化道与下消化道NETs，在患者性别、肿瘤直径及组织病理分型方面是存在统计学差异的。</p><p>本研究仅为单中心、回顾性研究，缺乏对于消化系统NETs疾病的发生发展机制、临床转归等方面的深入探讨，对于消化系统NETs的预防及预后方面尚不能得出实用性方案。因此，我们需要在此基础上进行多中心、大样本的研究，并结合流行病学数据加以分析，进一步完善肿瘤诊断及分类、分期标准，从而改善对NETs的诊治及预防措施，降低其发病率及死亡率。</p></sec><sec id="s9"><title>文章引用</title><p>党智萍,于 婷,翟慧敏,王诗梦,孔心涓. 245例消化系统神经内分泌肿瘤的内镜表现及病理特征分析Endoscopic Manifestations and Pathological Features of 245 Cases of Neuroendocrine Tumors in the Digestive System[J]. 临床医学进展, 2020, 10(11): 2444-2450. https://doi.org/10.12677/ACM.2020.1011369</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38482-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Oberg, K. (2010) Neuroendocrine Tumors (NETs): Historical Overview and Epidemiology. Tumori, 96, 797-801.  
&lt;br&gt;https://doi.org/10.1177/030089161009600530</mixed-citation></ref><ref id="hanspub.38482-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Caplin, M.E., Baudin, E., Ferolla, P., et al. (2015) Pulmonary Neuroendocrine (Carcinoid) Tumors: European Neuroendocrine Tumor Society Expert Consensus and Recommendations for Best Practice for Typical and Atypical Pulmonary Carcinoids. Annals of Oncology, 26, 1604-1620. &lt;br&gt;https://doi.org/10.1093/annonc/mdv041</mixed-citation></ref><ref id="hanspub.38482-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Fitzgerald, T.L., Dennis, S.O., Kachare, S.D., et al. (2015) Increasing Incidence of Duodenal Neuroendocrine Tumors: Incidental Discovery of Indolent Disease? Surgery, 158, 466-471. &lt;br&gt;https://doi.org/10.1016/j.surg.2015.03.042</mixed-citation></ref><ref id="hanspub.38482-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">王霄, 宋争放, 姚文秀, 等. 胃肠胰神经内分泌瘤的临床病理特点及预后的多因素分析[J]. 中华医学杂志, 2013, 93(18): 1411-1414.</mixed-citation></ref><ref id="hanspub.38482-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Dasari, A., Shen, C., Halperin, D., et al. (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncology, 3, 1335-1342.  
&lt;br&gt;https://doi.org/10.1001/jamaoncol.2017.0589</mixed-citation></ref><ref id="hanspub.38482-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">李增山. 胃肠胰神经内分泌肿瘤分类及病理学进展[J]. 浙江大学学报(医学版), 2016, 45(1): 10-23.</mixed-citation></ref><ref id="hanspub.38482-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Vinik, A.I., Woltering, E.A., Warner, R.R., et al. (2010) NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor. Pancreas, 39, 713-734. &lt;br&gt;https://doi.org/10.1097/MPA.0b013e3181ebaffd</mixed-citation></ref><ref id="hanspub.38482-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Nagtegaal, I.D., Odze, R.D., Klimstra, D., et al. (2020) The 2019 WHO Classification of Tumours of the Digestive System. Histopathology, 76, 182-188. &lt;br&gt;https://doi.org/10.1111/his.13975</mixed-citation></ref><ref id="hanspub.38482-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Yao, J.C., Hassan, M., Phan, A., et al. (2008) One Hundred Years after “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. Journal of Clinical Oncology, 26, 3063-3072.  
&lt;br&gt;https://doi.org/10.1200/JCO.2007.15.4377</mixed-citation></ref><ref id="hanspub.38482-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Desserud, K.F., Bukholm, I. and Søreide, J.A. (2017) Compensation Claims for Sub-Substandard Care of Patients with Gastroentero-Pancreatic Neuroendocrine Tumors: A Nationwide Descriptive Study of Cases between 2005-2016 in Norway. Anticancer Research, 37, 5667-5671. &lt;br&gt;https://doi.org/10.21873/anticanres.12002</mixed-citation></ref><ref id="hanspub.38482-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Russolillo, N., Vigano, L., Razzore, P., et al. (2015) Survival Prognostic Factors of Gastro-Enteric-Pancreatic Neuroendocrine Tumors after Primary Tumor Resection in a Single Tertiary Center: Comparison of Gastro-Enteric and Pancreatic Locations. European Journal of Surgical Oncology, 41, 751-757. &lt;br&gt;https://doi.org/10.1016/j.ejso.2015.02.011</mixed-citation></ref><ref id="hanspub.38482-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Al-Risi, E.S., Al-Essry, F.S. and Mula-Abed, W.S. (2017) Chromogranin A as a Biochemical Marker for Neuroendocrine Tumors: A Single Center Experience at Royal Hospital, Oman. Oman Medical Journal, 32, 365-370.  
&lt;br&gt;https://doi.org/10.5001/omj.2017.71</mixed-citation></ref><ref id="hanspub.38482-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">郭林杰, 唐承薇. 中国胃肠胰神经内分泌肿瘤临床研究现状分析[J]. 胃肠病学, 2012, 17(5): 276-278.</mixed-citation></ref><ref id="hanspub.38482-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">高尤亮, 王晨, 曾德华, 等. 神经内分泌肿瘤714例临床病理分析[J]. 海南医学, 2013, 24(2): 285-287.</mixed-citation></ref><ref id="hanspub.38482-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Garcia-Carbonero, R., Capdevila, J., Crespo-Herrero, G., et al. (2010) Incidence, Patterns of Care and Prognostic Factors for Outcome of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE). Annals of Oncology, 21, 1794-1803. &lt;br&gt;https://doi.org/10.1093/annonc/mdq022</mixed-citation></ref><ref id="hanspub.38482-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">苏惠, 李娜, 王海红, 等. 167例胃肠道神经内分泌肿瘤的内镜表现及病理特征回顾性分析[J]. 胃肠病学和肝病学杂志, 2019, 28(4): 405-409.</mixed-citation></ref><ref id="hanspub.38482-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Rindi, G., Bordi, C., La Rosa, S., et al. (2011) Gastroenteropancreatic (Neuro)endocrine Neoplasms: The Histology Report. Digestive and Liver Disease, 43, S356-S360. &lt;br&gt;https://doi.org/10.1016/S1590-8658(11)60591-4</mixed-citation></ref><ref id="hanspub.38482-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Osamura, R.Y. (2014) Current Concept of Neuroendocrine Tumors (NET): Its Changes for the Past 20 Years. Pathology, 46, S1. &lt;br&gt;https://doi.org/10.1097/01.PAT.0000454055.93030.32</mixed-citation></ref><ref id="hanspub.38482-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Uccella, S., Sessa, F. and La Rosa, S. (2015) Diagnostic Approach to Neuroendocrine Neoplasms of the Gastrointestinal Tract and Pancreas. Turk Patoloji Dergisi, 31, 113-127. &lt;br&gt;https://doi.org/10.5146/tjpath.2015.01319</mixed-citation></ref><ref id="hanspub.38482-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">顾健, 焦宇飞. 胃肠胰神经内分泌肿瘤病理学特征与分级[J]. 现代肿瘤医学, 2106, 24(16): 2648-2651.</mixed-citation></ref><ref id="hanspub.38482-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Fan, J.-G., Kim, S.-U. and Wong, V.W.-S. (2017) New Trends on Obesity and NAFLD in Asia. Journal of Hepatology, 67, 862-873. &lt;br&gt;https://doi.org/10.1016/j.jhep.2017.06.003</mixed-citation></ref><ref id="hanspub.38482-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Yazici, C. and Boulay, B.R. (2017) Evolving Role of the Endoscopist in Management of Gastrointestinal Neuroendocrine Tumors. World Journal of Gastroenterology, 27, 4847-4855. &lt;br&gt;https://doi.org/10.3748/wjg.v23.i27.4847</mixed-citation></ref><ref id="hanspub.38482-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">He, L., Deng,, T. and Luo, H.S. (2015) Efficacy and Safety of Endoscopic Resection Therapies for Rectal Carcinoid Tumors: A Meta-Analysis. Yonsei Medical Journal, 56, 72-81.</mixed-citation></ref></ref-list></back></article>